SUMMARY OF PRODUCT CHARACTERISTICS ENGLISH Dolol 50 mg capsules
|
|
- Britton McBride
- 6 years ago
- Views:
Transcription
1 SUMMARY OF PRODUCT CHARACTERISTICS ENGLISH Dolol 50 mg capsules 1. NAME OF THE MEDICINAL PRODUCT 1
2 Dolol 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 capsule contains 50 mg Tramadol hydrochloride corresponding to 44 mg tramadol. For a full list of excipients, see section PHARMACEUTICAL FORM Capsules, hard White opaque capsules containing a white and odourless powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of moderate to severe pain. 4.2 Posology and method of administration The dose should be adjusted to the intensity of the pain and the sensitivity of the individual patient. The lowest effective dose for analgesia should generally be selected. As for all opioid analgesics the dose of tramadol, with regards to the severity of the pain and sensitivity of the patient, should be administered in the lowest possible dose to offer the individual patient a clinical sufficient pain relief. In patients not requiring fast analgesia, tolerability may be improved by initiating therapy at lower doses and extended intervals and titrating up (e.g. chronic pains and/or cancer patients). After long-term use, psychiatric and physical dependence may develop. Therefore it is very important not to administer tramadol for a longer period of time than absolutely necessary (see 4.4 and 4.8). Careful and regular monitoring should be carried out to establish whether and to what extend further treatment is necessary. Discontinuation of therapy should be carried out gradually in patients who may have developed physical dependence to avoid precipitating withdrawal symptoms. Adults and children over 15 years: mg 3-4 times daily. Maximum 400 mg daily. Children Dolol 50 mg capsules are not recommended for use in children below 15 years. Geriatric patients A dose adjustment is not usually necessary in patients up to 75 years without clinically manifest hepatic or renal insufficiency. In elderly patients over 75 years elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements. Renal insufficiency/dialysis and hepatic impairment In patients with renal and/or hepatic insufficiency the elimination of tramadol is delayed. In these patients prolongation of the dosage intervals should be carefully considered according to the patient's requirements. Hepatic impairment: Tramadol is eliminated primarily via hepatic metabolism. Elimination half-life increases to 13.3 hours (oral dosing) in patients with hepatic insufficiency vs. 5.1 hours in normal subjects. 2
3 In patients with cirrhosis the maximum oral dose is 50 mg every 12 hours. Renal impairment: If creatinine clearance is less than 30 min/ml the dosing interval should be increased to 12 hours. The maximum daily dose is 200 mg. At end stage renal disease (creatinine clearance < 10 ml/min) a dose of 50 mg every 12 hours is recommended. Geriatric patients 4.3 Contraindications Hypersensitivity to tramadol or any of the excipients, or to opioids. Must not be used in patients suffering from uncontrolled epilepsy, acute intoxication by alcohol, hypnotics, analgesics or other medicaments that act on the central nervous system. Simultaneous administration of an MAO-inhibitor or within 2 weeks after stopping treatment with MAOinhibitors. Acute respiratory depression. Tramadol must not be used for narcotic withdrawal treatment. 4.4 Special warnings and precautions for use Tramadol should be used with caution in persons being treated with medicine lowering the convulsion threshold (MAO-inhibitors, tricyclic antidepressants and selective serotonin reuptake inhibitors). Tramadol should also be used with caution in patients suffering from head trauma with increased intracranial pressure, severe liver disease, severe renal failure, seizure liability, shock, severe respiratory depression with concomitant treatment with CNS depressants. (See also 4.5) Tramadol is not suitable as substitute in opioid dependency and cannot suppress morphine abstinence. Tramadol has addictive properties. Increased tolerance and psychological and physical dependence can develop following long-term medication. Cases of dependence to and abuse of tramadol have been reported. Withdrawal symptoms such as anxiety, sweating, nausea, diarrhoea, tremors and insomnia have been reported following discontinuation of treatment. (see Section 4.8). In patients with a history of drug abuse, Dolol should only be prescribed for short-term use and under careful medical supervision. For the moment, should not be used in persons under full anaesthetic. (Experience missing). Convulsions have been reported in patients receiving tramadol at the recommended dose levels. The risk may be increased when doses of tramadol exceed the recommended upper daily dose limit (400 mg). In addition, tramadol may lower the seizure threshold (see also 4.5). Patients with epilepsy or those susceptible to seizures should only be treated with tramadol if there are compelling circumstances. Patients with impaired lung function e.g. chronic obstructive lung disease or uncontrolled asthma may be at risk for respiratory depression and tramadol should be used with great caution. Decreased liver- or kidney function: Patients with cirrhosis or with end-stage renal disease (creatinine clearance 30 ml/min) have slower elimination of tramadol and its pharmacologically active metabolite. Thus, the dosing interval should be doubled in these patients. (See also 4.2) 4.5 Interaction with other medicinal products and other forms of interaction Alcohol, hypnotics and psychotherapeutic agents with sedative effect may enhance the CNS-depressive effect. (See also 4.8) Should not be administered to patients undergoing or having undergone treatment with MAO-inhibitors within the last two weeks. (See also 4.3) 3
4 Enzyme inducers, e.g. carbamazepine, may lower plasma tramadol concentration and diminish or shorten its analgesic effect. Simultaneous administration with antagonist opioids (e.g. nalbuphine, pentazocine) may reduce the analgesic effect by competitive blocking of the receptors. Concomitant administration of opioid agonist (e.g. buprenorphine) can cause addictive CNS depression because the use of other analgesics in combination with tramadol add a significant CNS and respiratory depression. Tramadol can induce convulsions and increase the potential for selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antipsychotics and other seizure threshold-lowering medicinal products (such as bupropion, mirtazapine, tetrahydrocannabinol) to cause convulsions. The risk of convulsions is increased with concomitant administration of other seizure-lowering drugs e.g. selective serotonin reuptake inhibitors, tricyclic anti-depressants, antipsychotics and bupropion. Concomitant therapeutic use of tramadol and serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors (see section 4.3), tricyclic antidepressants and mirtazapine may cause serotonin toxicity. Serotonin syndrome is likely when one of the following is observed: Spontaneous clonus Inducible or ocular clonus with agitation or diaphoresis Tremor and hyperreflexia Hypertonia and body temperature > 38 C and inducible or ocular clonus. Withdrawal of the serotonergic drugs usually brings about a rapid improvement. Treatment depends on the type and severity of the symptoms. Drugs that inhibit the CYP3A4 enzyme (ketoconazol, itraconazole, fluconazole and erythromycin) may inhibit the elimination of tramadol and its active metabolite and thus, increase the plasma concentrations of the two substances. The clinical effects of this possible interaction have not been studied. With concomitant administration of serotonergic drugs, there have been isolated reports of cases of serotonin syndrome. Discontinuation of treatment with the serotonergic drugs ususally results in a swift improvement of the symptoms. The need for further drug treatment is dependent on the type and seriousness of the symptoms observed. Caution should be exercised during concomitant treatment with tramadol and coumarin anticoagulantia (e.g. warfarin) due to reports of increased INR and ecchymoses in some patients on anticoagulantia. 4.6 Pregnancy and lactation Pregnancy Studies in animals have shown reproductive toxicity under very high doses (See also 5.3). No studies have been performed on the use of tramadol early in human pregnancy, but during labour the analgesic effect of 100 mg of tramadol was reported similar to 75 or 100 mg of pethidine, but with little to no depressant effect on the child. Tramadol administered before or during birth does not affect uterine contractility. The transplacental transfer of tramadol in delivering women occurred with a mean ratio of tramadol concentrations in the umbilical cord and maternal serum of As there is insufficient data available on the safety of tramadol in human pregnancy, tramadol should therefore not be used in pregnant women. Lactation 4
5 During lactation about 0.1% of the maternal dose is secreted into the milk. Available data is inconclusive or is inadequate to determine infant risk when used during breastfeeding. Dolol is not recommended during breast-feeding. After a single administration of tramadol it is not usually necessary to interrupt breast-feeding. 4.7 Effects on ability to drive and use machines Dolol capsules may cause drowsiness and this effect may be potentiated by alcohol, antihistamines and other CNS depressants. If patients are affected, they should be warned not to drive or operate machinery. 4.8 Undesirable effects Physical dependence and withdrawal symptoms (restlessness, anxiety, nervousness, sleeplessness, hyperkinesia, tremor and gastrointestinal disorders) may occur in connection with therapeutic doses (see Section 4.4). Withdrawal symptoms are in accordance with those occurring in connection with opiate withdrawal symptoms. In general, the incidence of predictable undesirable effects is dependent on dosage, timing of administration and duration of treatment (see section 4.2 and 4.4). By using the lowest effective dose for the minimum possible period of time, undesirable effects can be minimised. The more severe adverse effects of tramadol are respiratory depression, circulatory failure and rarely anaphylactic reactions. The most commonly observed adverse reactions are nausea, dizziness, headache, drowsiness, fatigue and restlessness. Cardiac disorders: Uncommon ( 1/1,000 to <1/100): There may be effects on cardiovascular regulation (palpitation, tachycardia, postural hypotension or circulatory failure) especially after intravenous administration or in physically stressed patients. Very rare (<1/10.000): Myocardial ischemia, abnormal electrocardiograms, hypertension. Nervous system disorders: Very common ( 1/10): Dizziness and somnolence, fatigue, headache. Rare ( 1/10,000 to <1/1,000): Hyperkinesia, tremor and epileptiform convulsions Very rare (<1/10.000): Ataxia Eye disorders: Rare ( 1/10,000 to <1/1,000): Blurred vision Respiratory, thoracic and mediastinal disorders Very rare (<1/10.000): Respiratory depression and eventually pulmonary oedema Gastrointestinal disorders: Very common ( 1/10): Nausea, diarrhoea Common ( 1/100 to <1/10): Constipation, vomiting and dry mouth Uncommon ( 1/1,000 to <1/100): Gatrointestinal irritation (bloated stomach) Rare ( 1/10,000 to <1/1,000): Changes in appetite Very rare (<1/10.000): Taste perversion. Hiccups. Renal and urinary disorders: Common ( 1/100 to <1/10): Micturition disorders and urinary retention Rare ( 1/10,000 to <1/1,000): Dysuria Skin and subcutaneous tissue disorders: Common ( 1/100 to <1/10): Increased sweating Uncommon ( 1/1,000 to <1/100): Dermal reactions (e.g. pruritus, urticaria, flush). Very rare (<1/10.000):Stevens-Johnson syndrome, toxic epidermal necrolysis. 5
6 Musculoskeletal and connective tissue disorders Common ( 1/100 to <1/10): Hypertonia Vascular disorders: Common ( 1/100 to <1/10): Vasodilation General disorders and administration site conditions: Rare ( 1/10,000 to <1/1,000): Allergic reaction (e.g. bronchospasm, angioedema) and anaphylactoid reaction have been reported. Hepatobiliary disorders: In isolated cases: increased liver enzyme values Psychiatric disorders: Rare ( 1/10,000 to <1/1,000): Sleep disturbances, nightmares, confusion and hallucinations. Dependence may occur after a longer period of treatment. Very rare (<1/10.000): Restlessness, anxiety, nervousness and sleeplessness. Changes in cognitive and sensorial capacity, depression, and suicidal ideation. Serotonin syndrome: Mental status changes, agitation, myoclonus, hyperreflexia, sweating, shivering, tremor, diarrhoea, incoordination, and fever. Nearly all the patients were taking concomitant medication known to increase brain serotonin levels. Others Very rare (<1/10.000): Psychological and/or physical dependence.withdrawal syndrome/reactions: agitation, anxiety, nervousness, insomnia, sweating, hyperkinesia, tremor, pains, gastrointestinal symptoms, upper respiratory symptoms, piloerection and hallucinations may occur if tramadol is abruptly discontinued. 4.9 Overdose Symptoms: Miosis, vomiting, convulsions, circulatory failure and consciousness disorders up to coma, sedation, respiratory depression up to respiratory arrest, eventually pulmonary oedema, tachycardia, hypertension, lethargy and rarely cardiovascular collapse. Treatment: Symptomatic treatment including maintaining respiration and circulation. The stomach should be emptied by vomiting (conscious patients) or gastric irrigation. Antidote: Naloxone is antidote for respiratory depression. Naloxone showed no effect on tramadol induced convulsions in experimental animals. In such cases diazepam should be given intravenously. Tramadol is not eliminated from the serum by haemodialysis or haemofiltration. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group, ATC code: N 02 AX 02 Tramadol is a cyclohexanol derivative, with morphine-like properties, and with central analgesic activity. Tramadol has a low affinity to opioid receptors, highest to µ-receptors. Furthermore, Tramadol enhances the endogenous pain modulation, partly by inhibition of the reuptake of Noradrenaline and Serotonine in the synaptic cleft, partly by increasing the release of Serotonine. The analgetic effect occurs about 1 hour after oral administration and lasts for a period of 4-8 hours. Respiration is not inhibited by the administration of therapeutic doses, but a respiratory depression may be seen if a dosis higher than that recommended is used, especially after parenteral administration. 5.2 Pharmacokinetic properties 6
7 Tramadol is quickly and almost completely absorbed from the gastrointestinal tract, independent of a concomitant intake of food. The bioavailability is about 68% due to first pass metabolism. Maximum plasma concentration is obtained after 2 hours. Tramadol is metabolised mainly in the liver by N- and O- demethylation and glucoronide conjugation of O-demethylation metabolites. The N-demethylation and O- demethylation are catalysed by the enzymes CYP3A4 and CYP2D6, respectively. O-desmethyl tramadol is pharmacologically active. The half-life of elimination is about 5-6 hours for Tramadol and 6-7 hours for O- desmethyl tramadol. The volume of distribution is about 300 l, which indicates a high tissue affinity. The protein binding is 20%. Tramadol crosses the blood-brain barrier and the placenta. A very small amount of Tramadol is excreted in breast milk. 90% of the administered dose is eliminated by renal excretion, 15% as unchanged. The remaining 10% is eliminated in the feces. The pharmacokinetic profile is linear within the theraputic dose range. The relationship between serum concentration and analgesic effect is dose dependent but with large deviations in the individual patients. 5.3 Preclinical safety data In animal studies an increased neonatal mortality was observed after administration of Tramadol. Animal studies with tramadol revealed at very high doses effects on organ development, ossification and neonatal mortality. Teratogenic effects were not observed. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Calcium hydrogen phosphate, anhydrous Magnesium stearate Silica, colloidal anhydrous Gelatin Titanium dioxide (E 171) 6.2 Incompatibilities Not applicable. 6.3 Shelf life 4 years. 6.4 Special precautions for storage This medicinal product does not require any special storage conditions. 6.5 Nature and contents of container Blister packaging made of white opaque PVC film and aluminium foil with a PVC/PVDC heat sealing lacquer. Pack sizes: 20, 100 and 5 x 50 capsules Not all pack sizes may be marketed. 6.6 Special precautions for disposal and other handling No special requirements 7
8 Any unused product or waste material should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER Nycomed Danmark A/S Langebjerg 1, P.O. Box 88 DK-4000 Roskilde Denmark 8. MARKETING AUTHORISATION NUMBER(S) DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 17 June DATE OF REVISION OF THE TEXT MM/YYYY09/2012 8
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Xymel SR 100 mg prolonged release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged release tablet contains 100 mg tramadol
More informationSummary of Product Characteristics Part IB1 Tramadol HCl Disphar druppels 100 mg/ml, oral drops Page 1 of 7
Tramadol HCl Disphar druppels 100 mg/ml, oral drops Page 1 of 7 1. NAME OF THE MEDICINAL PRODUCT Tramadol HCl Disphar druppels 100 mg/ml, oral drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationXTRAM. Composition Xtram 50 mg capsule Each capsule contains Tramadol HCl 50 mg
XTRAM Composition Xtram 50 mg capsule Each capsule contains Tramadol HCl 50 mg Capsules Action Tramadol is a centrally acting synthetic analgesic of the aminocyclohexanol group with opioid-like effects.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 50 mg/ml solution for injection for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tramadol Retard Actavis 100 mg prolonged-release tablets Tramadol Retard Actavis 150 mg prolonged-release tablets Tramadol Retard Actavis
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Tramadol 50mg Capsules Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50mg tramadol hydrochloride. For a full list of
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Xymel 50 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50 mg tramadol hydrochloride. Excipient(s) with
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationPART 1.B SPC, LABELLING AND PACKAGE LEAFLET
TRAMADOG, solution for injection Decentralised Procedure D195 February 2018 V3 Tramadol HCl 50 mg/ml Part 1.B SPC, Labelling and Package Leaflet PART 1.B SPC, LABELLING AND PACKAGE LEAFLET 1B- 1 ANNEX
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT YOCON-GLENWOOD Tablets 5 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains 5 mg yohimbine hydrochloride. For a full list of excipients, see section 6.1. 3
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationPACKAGE INSERT. The other ingredients are: sodium acetate and water for injection.
PACKAGE INSERT SCHEDULING STATUS Schedule 5 PROPRIETARY NAME AND DOSAGE FORM TRAMAL 100 Ampoules COMPOSITION Each ampoule contains tramadol hydrochloride 100 mg. The other ingredients are: sodium acetate
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tramadol 50 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50 mg of tramadol hydrochloride. Excipients
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule, hard contains tramadol hydrochloride 50 mg. For the full list of excipients,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 20 mg chewable tablets for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More information4.4 Special warnings and precautions for use
SUMMARY OF PRODUCT CHARACTERISTICS 4.3 Contraindications Durogesic is contraindicated in patients with known hypersensitivity to fentanyl or to the excipients present in the patch. Acute or postoperative
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Outer carton Multi-pack 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tramadol 50 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50 mg of tramadol hydrochloride. Excipients
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationP-RMS: FR/H/PSUR/0036/001
Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,
More informationNAME OF THE MEDICINAL PRODUCT IMODIUM CAPS. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg loperamide hydrochloride (HCl) per capsule.
NAME OF THE MEDICINAL PRODUCT IMODIUM CAPS QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg loperamide hydrochloride (HCl) per capsule. PHARMACEUTICAL FORM AND DESCRIPTION Capsules, hard White powder filled
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Morfin Abcur, 10 mg/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 10 mg morphine hydrochloride
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Citanest with Octapressin Dental 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Prilocaine Hydrochloride 30 mg (54 mg/1.8
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklo-f 500 mg film coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains tranexamic acid 500 mg For the full
More informationSUMMARY OF PRODUCT CHARACTERISTICS. One film-coated tablet contains 10 mg of cetirizine dihydrochloride.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin STADA 10 mg, film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 10 mg of cetirizine
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT ALVERINE Mayoly Spindler, 60 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 60 mg of alverine citrate.
More information3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides.
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mebeverine hydrochloride 135 mg coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains 135 mg of mebeverine
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacidipine 2 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg lacidipine. Excipient with known
More informationPrescribing and Administration of Analgesia within Maternity
Prescribing and Administration of Analgesia within Maternity CONTENTS Introduction and Who The Guideline Applies To... 2 UHL Paracetamol Prescribing Guideline... 2 Oral dosing... 2 Intravenous dosing...
More informationSummary of Product Characteristics
Summary of Product Characteristics Product Summary 1. Trade Name of the Medicinal Product Durogesic DTrans 12/25/50/75/100 Transdermal Patch 2. Qualitative and Quantitative Composition Each Durogesic DTrans
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT LoModine 2mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Loperamide hydrochloride 2mg For full list of excipients, see section
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 6 1. Name of the Medicinal Product Cycloserine 250mg Capsules 2. Qualitative and Quantitative Composition Each hard capsule contains: Cycloserine 250 mg For
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Loperamide hydrochloride 2mg For full list of excipients, see section 6.1 Contains lactose 100mg per capsule 3 PHARMACEUTICAL
More informationAVIOMARIN 50 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationSIBELIUM Capsules Janssen
SIBELIUM Capsules Janssen NAME OF THE MEDICINAL PRODUCT Trade name SIBELIUM International Non-Proprietary Name (Modified) (rinnm) flunarizine hydrochloride QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin Mylan 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg of cetirizine
More informationCONSUMER MEDICINE INFORMATION
CONSUMER MEDICINE INFORMATION Arrow - Tramadol Tramadol 50 mg capsules What is in this leaflet This leaflet answers some common questions about ARROW - TRAMADOL. It does not contain all of the available
More informationIMODIUM. Janssen Pharma
IMODIUM Janssen Pharma NAME OF THE MEDICINAL PRODUCT IMODIUM QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg loperamide hydrochloride (HCl) per capsule. PHARMACEUTICAL FORM AND DESCRIPTION Capsules, hard
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SimAlvia 60 mg/300 mg, soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each soft capsule contains 60 mg alverine citrate and
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationRE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act
22 January 2019 RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act Dear Healthcare Professional, This notification
More informationPRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets
PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H
More informationPackage leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride
Package leaflet: Information for the patient Cetirizin Sandoz 10 mg film-coated tablets cetirizine dihydrochloride [For medicine available only on prescription:] Read all of this leaflet carefully before
More informationXYZAL 5 MG FILM-COATED TABLET
XYZAL 5 MG FILM-COATED TABLET Levocetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Otrivin Menthol (without preservative) 1.0 mg/ml nasal spray, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 1.0 mg
More informationAPO-TRAMADOL CAPSULES. (1RS,2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol hydrochloride
APO-TRAMADOL CAPSULES NAME OF THE MEDICINE Tramadol Hydrochloride Chemical Name: (1RS,2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol hydrochloride Chemical Formula: C16 H25 NO2.HCl Molecular
More informationPackage leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate
Package leaflet: Information for the patient Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate Read all of this leaflet carefully before you start using this medicine because
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ondansetron Aristo 4 mg film-coated tablets Ondansetron Aristo 8 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Morphine hydrochloride 10 mg/ml equivalent to morphine 7.6 mg/ml.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Morfin Kalceks, 10 mg/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Morphine hydrochloride 10 mg/ml equivalent
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lopacut 2 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg of loperamide hydrochloride. For
More informationPRODUCT INFORMATION. Benadryl* for the Family Nightime Oral Liquid
Product description PRODUCT INFORMATION Benadryl* for the Family Nightime Oral Liquid Each 5 ml of Benadryl* Nightime oral liquid contains dextromethorphan hydrobromide 10 mg and diphenhydramine hydrochloride
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lidokain Isdin 40 mg/g cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g cream contains 40 mg lidocaine. Excipients: Propylene glycol
More informationTranslated from Latvian Approved by SAM on
Translated from Latvian SAM on 29.07.2010 1. NAME OF THE MEDICINAL PRODUCT FENKAROL 10 mg Tablets FENKAROL 25 mg Tablets FENKAROL 50 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance
More informationCHEMMART TRAMADOL SR TABLETS. (1RS,2RS)-2-[(dimethylamino)methyl)]-1-(3-methoxyphenyl)cyclohexanol hydrochloride.
Product Information- Australia CHEMMART TRAMADOL SR TABLETS NAME OF THE MEDICINE Tramadol hydrochloride Chemical Name: (1RS,2RS)-2-[(dimethylamino)methyl)]-1-(3-methoxyphenyl)cyclohexanol hydrochloride.
More informationCHEMMART TRAMADOL CAPSULES. (1RS,2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol hydrochloride
CHEMMART TRAMADOL CAPSULES NAME OF THE MEDICINE Tramadol Hydrochloride Chemical Name: (1RS,2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol hydrochloride Chemical Formula: C16 H25 NO2.HCl
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alfuzosin HCl Ranbaxy 10 mg tablets, prolonged-release tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg
More informationPRODUCT INFORMATION ZYDOL
PRODUCT INFORMATION ZYDOL i) Name of the Medicine Zydol Zydol contains tramadol hydrochloride known chemically as ( + ) -cis-2-(dimethylaminomethyl)- 1-(3-methoxyphenyl)-cyclohexanol hydrochloride with
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each capsule contains PARACETAMOL 500mg For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT PARACETAMOL 500mg CAPSULES Boots Paracetamol 500mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains PARACETAMOL
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT TRANSISOFT 8.5 g powder for oral solution in sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 8.5 g of macrogol
More informationSummary of Product Characteristics
TRANSLATION FROM LATVIAN Summary of Product Characteristics State Agency of Medicines, Director I.Adoviča /signature/ Registered No.10843-300708 1. NAME OF THE MEDICINAL PRODUCT ADAPTOL 500 mg Tabletes
More informationVALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics
Sandoz Business use only Page 1 of 5 Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Valeriaan Sandoz omhulde tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains
More informationCore Safety Profile. Pharmaceutical form(s)/strength: 5mg/ml and 25 mg/ml, Solution for injection, IM/IV FI/H/PSUR/0010/002 Date of FAR:
Core Safety Profile Active substance: Esketamine Pharmaceutical form(s)/strength: 5mg/ml and 25 mg/ml, Solution for injection, IM/IV P-RMS: FI/H/PSUR/0010/002 Date of FAR: 29.05.2012 4.3 Contraindications
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizine 10 mg Film-Coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg cetirizine dihydrochloride.
More informationCHEMMART TRAMADOL CAPSULES. (1RS,2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol hydrochloride
CHEMMART TRAMADOL CAPSULES NAME OF MEDICINE Tramadol Hydrochloride Chemical Name: (1RS,2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol hydrochloride Chemical Formula: C 16 H 25 NO 2.HCl Molecular
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT WICK Chesty Cough Syrup 200 mg/15 ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 15 ml syrup contains 200 mg guaifenesin. Each ml syrup
More informationEmergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.
1. NAME OF THE MEDICINAL PRODUCT: Levonorgestrel Tablets 1.5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each tablet contains levonorgestrel 1.5 mg. Excipient with known effect: Each tablet contains
More informationPackage leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride
Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationEU Core Safety Profile
EU Core Safety Profile Active Substance: Triazolam Brand Names: HALCION, SOMESE Pharmaceutical form(s)/strength: Tablets RMS: Finland Date: 9 th Dec 2013 Supersedes: 24 th May 2010 4.3. Contraindications
More information